As an advanced practice nurse, it is your responsibility to recommend appropriate treatment options for patients with cardiovascular disorders. To ensure the safety and effectiveness of drug therapy, advanced practice nurses must consider aspects that might influence pharmacokinetic and pharmacodynamic processes such as medical history, other drugs currently prescribed, and individual patient factors.
consider the following scenario:
Patient HM has a history of atrial fibrillation and a transient ischemic attack (TIA). The patient has been diagnosed with type 2 diabetes, hypertension, hyperlipidemia and ischemic heart disease. Drugs currently prescribed include the following:
· Warfarin 5 mg daily MWF and 2.5 mg daily T, TH, Sat, Sun
· Aspirin 81 mg daily
· Metformin 1000 mg po bid
· Glyburide 10 mg bid
· Atenolol 100 mg po daily
· Motrin 200 mg 1–3 tablets every 6 hours as needed for pain
Evidence-based clinical practice guidelines are fundamental to clinical practice, as they assist providers with clinical decision making.
I have attached some applicable guidelines below for your reference.
Write a 2- to 3-page paper that addresses the following:
· Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.
· Describe how changes in the processes might impact the patient’s recommended drug therapy. Be specific and provide examples.
· Explain how you might improve the patient’s drug therapy plan and explain why you would make these recommended improvements
Meet Dr. Norbert Myslinski as he discusses ACE inhibitors, angiotensin inhibitors, beta-blockers, calcium channel blockers, and diuretics as different categories of hypertension drugs. What potential drugs might be best recommended for patients suffering from hypertension? (8m)
2018 AHA-ACC Guideline on Mgmt Blood Cholesterol.pdf
2017 ACC-AHA-HFSA Guideline Mgmt HF.pdf
ASH 2018 Guidelines Mgmt of VTE_Optimal Anticoag.pdf
2019 AHA-ACC-HRS Guideline for Mgmt A Fib.pdf
2017 AHA-ACC Guideline Mgmt Valvular Heart Disease.pdf